-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Initiates Coverage On Avalo Therapeutics with Market Outperform Rating, Announces Price Target of $52

Benzinga·04/06/2026 09:46:48
Listen to the news
Citizens analyst Jason Butler initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperform rating and announces Price Target of $52.